It appears that Besins Healthcare, the manufacturer of AndroGel, will not be in any position to duck testosterone side effects lawsuits quite so easily.
According to court records, Besins asked to be excused from multidistrict litigation given, in the Belgian pharmaceutical’s view, its limited exposure to the US market and thus, Besins’ claim that the Illinois court tasked with consolidating cases in multidistrict litigation has insufficient personal jurisdiction.
AndroGel, Besins maintained, is manufactured in France and Besins neither sells, nor markets the drug in the US [that task is entrusted to another company, AbbVie under contract and licensing agreement].
However, US District Judge Matthew F. Kennelly wasn’t buying what Besins was selling.
“Over the course of more than 16 years, billions of dollars’ worth of AndroGel has been sold nationwide, and Besins' revenues from United States AndroGel sales exceed $600 million,” the judge said. “Though Besins does not appear to have considerable influence or control over sales and marketing, its employees receive periodic updates about the United States market for AndroGel and about sales and marketing generally.”
Testosterone therapy has been around for decades, originally approved by the US Food and Drug Administration (FDA) for the treatment of hypogonadism – in other words, a dangerously low [or even absent] level of testosterone in men. Such low levels can carry serious health risks for those affected – and even with known testosterone side effects such as testosterone stroke, heart attack or even testosterone death, the benefits for those indicated for testosterone therapy outweighs the risks.
However, that isn’t the case for healthy men seeking to turn back the clock.
Plaintiffs in testosterone heart attack lawsuits assert that testosterone replacement therapy manufacturers patently ‘invented’ a disease – ‘Low-T’ – in an effort to move more product and create a new and growing market for testosterone drugs through an association with aging male Baby Boomers.
It is natural for testosterone levels to diminish somewhat as men age. It is also normal for testosterone levels to fluctuate during the day or across several days. In other words, one single reading of testosterone in one day is not a sufficient marker of true testosterone level and supply.
One single snapshot does not a story make.
Manufacturers were nonetheless wildly successful in creating, and marketing ‘Low-T’ to a large cross-section of the male population, succeeding in creating new sources of revenue for manufacturers and a host of new health concerns for otherwise healthy men, or so it has been alleged.
Various studies have determined that increasing levels of testosterone in otherwise healthy men with adequate levels of testosterone to begin with can result in health risks. It has been found that levels of testosterone that are too high can effectively over-activate red blood cells, effectively thickening the blood at a time when it’s prudent to thin blood to avoid testosterone heart attack and stroke.
While there are benefits, for these patients the risks of testosterone therapy far outweigh the benefits.
Various plaintiffs have asserted they were reasonably healthy to begin with prior to starting on testosterone replacement therapy at the behest of aggressive marketing on the part of manufacturers alleged to have withheld the risks of such treatment from consumers. Many plaintiffs went on to suffer heart attacks and testosterone stroke as the result of using testosterone replacement therapy.
READ MORE TESTOSTERONE TREATMENT LEGAL NEWS
Testosterone lawsuits have also been filed by health insurers, claiming to have funded testosterone replacement therapies that were medically unnecessary.
While testosterone drugs have always carried FDA approval for hypogonadism, the latter remains the only approved indication. Use of TRTs for so-called ‘Low-T’ is considered off-label and therefore, patently illegal according to current laws.
AndroGel manufacturer Besins remains in the defendant pool.
The case is In re: Testosterone Replacement Therapy Products Liability Litigation, Case No. 1:14-cv-01748, MDL number 2545, in the US District Court for the Northern District of Illinois.